ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity;L'ADMA est corrélée à l'insulinorésistance au stade précoce de diabète indépendamment de la CRP ultrasensible et de la masse grasse

Annales d'Endocrinologie

Volumn 71, Issue 4, 2010, Pages 303-308

  Nakhjavani, M ^a   Karimi Jafari, H ^a   Esteghamati, A ^a   Khalilzadeh, O ^a   Asgarani, F ^a   Ghadiri Anari, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADMA; Diabetes mellitus; HOMA; Hs CRP; Insulin resistance

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DIABETES MELLITUS, TYPE 2; FASTING; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 77956227796     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2010.02.026     Document Type: Article

References (46)

1. Abdul-Ghani M.A., Tripathy D., DeFronzo R.A. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
2. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Berkowitz K., Marroquin A., et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000, 49:782-788.
3. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399-404.
4. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 2006, 116:1813-1822.
5. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 14:222-231.
6. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
7. Anan F., Takahashi N., Nakagawa M., Ooie T., Saikawa T., Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005, 54:552-558.
8. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
9. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., Hu F.B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004, 27:889-894.
10. Mojiminiyi O.A., Abdella N., Moussa M.A., Akanji A.O., Al Mohammedi H., Zaki M. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002, 58:37-44.
11. Brillante D.G., O'Sullivan A.J., Johnstone M.T., Howes L.G. Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. Clin Sci (Lond) 2008, 114:139-147.
12. Brillante D.G., O'Sullivan A.J., Howes L.G. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc Health Risk Manag 2009, 5:73-78.
13. Oguz A., Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008, 49:303-311.
14. Chan N.N., Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 2002, 45:1609-1616.
15. Anderson J.L., Carlquist J.F., Roberts W.L., Horne B.D., May H.T., Schwarz E.L., et al. Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?. Am Heart J 2007, 153:67-73.
16. Krzyzanowska K., Mittermayer F., Krugluger W., Schnack C., Hofer M., Wolzt M., et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006, 189:236-240.
17. Telejko B, Zonenberg A, Kuzmicki M, Modzelewska A, Niedziolko-Bagniuk K, Ponurkiewicz A, et al. Circulating asymmetric dimethylarginine, endothelin-1 and cell adhesion molecules in women with gestational diabetes. Acta Diabetol 2009;46(4):303-8. [Epub 2009 Jan 13].
18. Smith C.L. C-reactive protein and asymmetric dimethylarginine: markers or mediators in cardiovascular disorders?. Curr Pharm Des 2007, 13:1619-1629.
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31 (Suppl)1:S55-60.
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
21. Pereira E.C., Ferderbar S., Bertolami M.C., Faludi A.A., Monte O., Xavier H.T., et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem 2008, 41:1454-1460.
22. Murray-Rust J., Leiper J., McAlister M., Phelan J., Tilley S., Santa Maria J., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001, 8:679-683.
23. Yamagishi S., Ueda S., Okuda S. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Med Hypotheses 2007, 69:922-924.
24. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987-992.
25. Flores-Alfaro E., Parra-Rojas I., Salgado-Bernabe A.B., Chavez-Maldonado J.P., Salazar-Martinez E. Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects. Circ J 2008, 72:1170-1174.
26. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
27. King D.E., Mainous A.G., Buchanan T.A., Pearson W.S. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003, 26:1535-1539.
28. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
29. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
30. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
31. Morin-Papunen L., Rautio K., Ruokonen A., Hedberg P., Puukka M., Tapanainen J.S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88:4649-4654.
32. Feldman M., Jialal I., Devaraj S., Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001, 37:2036-2041.
33. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
34. Perticone F., Sciacqua A., Maio R., Perticone M., Maas R., Boger R.H., et al. Asymmetric dimethylarginine L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005, 46:518-523.
35. Schulze F., Lenzen H., Hanefeld C., Bartling A., Osterziel K.J., Goudeva L., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J 2006, 152:493. e1-8.
36. Toutouzas K., Riga M., Stefanadi E., Stefanadis C. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm Metab Res 2008, 40:655-659.
37. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.
38. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2009. [Epub ahead of print] PMID: 19168237, doi:10.1016/j.ijcard.2008.12.131.
39. McLaughlin T., Stuhlinger M., Lamendola C., Abbasi F., Bialek J., Reaven G.M., et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006, 91:1896-1900.
40. Wang T.D., Chen W.J., Cheng W.C., Lin J.W., Chen M.F., Lee Y.T. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006, 98:1057-1062.
41. Reimann M., Schutte A.E., Malan N.T., Schwarz P.E., Benndorf R.A., Schulze F., et al. Asymmetric dimethylarginine is associated with parameters of glucose metabolism in Caucasian but not in African women from South Africa. Exp Clin Endocrinol Diabetes 2007, 115:600-605.
42. Cetinalp-Demircan P., Can A., Bekpinar S., Unlucerci Y., Orhan Y. Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease. Endocrine 2007, 31:100-104.
43. Konukoglu D., Firtina S., Serin O. The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008, 57:110-115.
44. Esteghamati A., Khalilzadeh O., Anvari M., Meysamie A., Abbasi M., Forouzanfar M., et al. The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia 2009, 52:1520-1527.
45. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
46. Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Furuta M., Araki-Sasaki R., et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001, 24:362-365.